Login / Signup

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.

Lovisa FalkmanAnders SundinBritt SkogseidJohan BotlingYvette BernardoGöran WallinLiang ZhangStaffan WelinIeva LaseKazhan MollazadeganJoakim Crona
Published in: Upsala journal of medical sciences (2024)
-mutated NEC is sensitive to treatment with BRAF- and MEK-inhibitor combination. These results further support that DNA sequencing should be considered as standard of care in NECs to screen for potential treatment targets.
Keyphrases
  • healthcare
  • palliative care
  • stem cells
  • high throughput
  • signaling pathway
  • pi k akt
  • wild type
  • circulating tumor
  • smoking cessation
  • circulating tumor cells
  • chemotherapy induced